Cingulate Inc. (CING): debt financing — Cingulate completes $6M debt financing, appoints Bryan Downey as CCO

Cingulate Inc.

Issued $6.57M unsecured promissory note at 9% interest, maturing 18 months, to Avondale Capital for $6M net proceeds.
Bryan Downey appointed Chief Commercial Officer; granted 30,000 options at $3.80/share, vesting over 4 years.
Cash runway extended into Q2 2026; proceeds for working capital and general corporate purposes.
FDA accepted NDA for CTx-1301 (ADHD); PDUFA target action date May 31, 2026.
Note includes monthly redemption up to $660k after PDUFA; company can defer up to 2 redemptions with 1% fee.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Cingulate Inc. incurred loan of $6,570,000 with Avondale Capital, LLC at 9% per annum maturing 18 months after its issuance date.

Instrument: loan
Principal: $6,570,000
Counterparty: Avondale Capital, LLC
Rate: 9% per annum
Maturity: 18 months after its issuance date
Event: incurrence

Exact text from the filing

On November 7, 2025, Cingulate, Inc. (the “Company”), entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with Avondale Capital, LLC, a Utah limited liability company (“Lender”), pursuant to which the Company issued and sold to Lender an unsecured promissory note (the “Note”) in the amount of $6,570,000 (the “Principal Amount”).

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

Cingulate Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-021410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.